IDM 2

Drug Profile

IDM 2

Alternative Names: Bexidem; IDM-2

Latest Information Update: 22 Feb 2010

Price : $50

At a glance

  • Originator IDM Pharma
  • Developer Takeda America Holdings
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bladder cancer

Most Recent Events

  • 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
  • 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
  • 13 Jun 2006 The US FDA has conducted a Special Protocol Assessment on the planned US phase II/III clinical trial for superficial bladder cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top